

Santen UK Limited
Salisbury Hall
St Albans
AL2 1BU
Tel +44 (0)1727 615110

www.santen.ie

## **EFPIA Disclosure Methodology**

This methodological note is intended to help readers understand the disclosure of data regarding Transfers of Value (TOV) to Healthcare Professionals (HCPs) and Healthcare Organisations (HCOs) in Ireland during the calendar year 2023 made by Santen UK Limited (Santen). We have summarised below the methodologies used by Santen in preparing our disclosures and identifying each category of TOV.

Santen engaged with the ophthalmology community through supporting educational meetings which involved TOVs for speakers, support of HCPs to attend such meetings and sponsorship for a small number of meetings organised by HCOs in 2023. TOVs made by other parts of Santen during 2023 have been reported as part of the Ireland disclosure.

Santen did not make any TOVs to patient organisations in Ireland during 2023.

We marketed prescription-only medicines and one device in 2023. Santen did not make any TOVs related to devices in 2023.

Santen UK uses a management tool (CRM) through which all contacts and meetings with HCPs are reported.

Using this tool, we have captured and categorised all TOV agreements made in Ireland during 2023, including the following details:

- The HCP or HCO who received the TOV
- Period covered by the TOV
- Type of TOV, for example, consultancy, speaker fees, sponsorship and expenses incurred
- Value of the TOV, for example for fees and expenses incurred
- Currency in which the TOV was made
- Date TOV was made
- Whether consent to disclose individual data was gained, not given, or withdrawn

The data collected in the CRM have been submitted to a third-party organisation who produced the disclosure report by country of HCP/HCO residence.

Where a HCP has given consent to disclose some parts of their TOV individually but consent is either not given or is missing and/or unknown for other parts, Santen has disclosed all TOV in aggregate. This does not apply to any HCPs in 2023.

Please find below some more information to support the understanding of our disclosure:

Contracts with HCPs/HCOs	Contracts in 2021 were signed for each specific service provided, for example for each speaker engagement. There are no multi-year contracts between Santen and HCPs. Transfers of value from 2021 onwards are disclosed according to the date of payment from Santen. Where a multi-year contract is in place, the TOV is disclosed based on the payment dates of the TOV.
'Donations', 'Grants' and 'Sponsorship'	Santen defines these as "one-way" TOVs: for Donations there is no specific purpose defined for the TOV but for Grants there is a specified purpose; in both cases the company would not expect to receive a service in return.
	Santen provided support to HCPs and HCOs during 2022 and defines 'Contracted Services' and 'Sponsorship' as a "two-way" TOV: in return for the TOV Santen received defined service, such as a space at a congress for an exhibition stand, consultancy or speaking engagement. There is an exception of the "two-way rule" for sponsorship to attend scientific congresses, for which there is no expected service in return.
Obtaining disclosure consent	Santen requested all HCPs who received TOVs to give us their consent to disclose their individual details at the time of the specific TOV, using separate disclosure agreements. This was recorded in our CRM system.
Tax considerations	We do not deduct any taxes from our TOVs, but we make it clear in our HCP contracts that taxes where applicable must be paid by the HCP.
Payments	Disclosure has been made based on the payment date of the TOV.
	Where payments have been made by a third party for travel expenses on behalf of Santen, these are disclosed based on the date of travel.  Where payments for accommodation have been made as part of a 24hr rate, the cost
	of the 24hr rate has been disclosed.
VAT	VAT is not paid on fees to HCPs but is included in the payment of expenses. Where VAT has been included in payments to HCOs, we have disclosed the VAT as part of the Transfer of Value.
Currency	The great majority of our TOVs were paid in Euros, but where TOVs were made in different currencies, these were converted to Euros at the prevailing exchange rate.
Cross-border payments	There were no cross-border engagements in 2023.
Non-monetary transfers of	Disclosure of non-monetary transfers of value is made at the equivalent value in
value	monetary terms.
Research and Development	For the purpose of disclosure, R&D TOVs are transfers of value to a HCP or HCO related to the planning or conduct of: - non-clinical studies (as defined in the OECD Principles of Good Laboratory Practice) - clinical trials (as defined in Directive 2001/20/EC) - non-interventional studies that are prospective in nature and involve the collection of data from, or on behalf of, individual or groups of health professionals specifically for the study. There are no TOVs related to Research and Development activities in 2023.